UBS has reconfirmed its 'Buy' rating for MetLife Inc. (NYSE:MET) and raised its price target to $102, signaling confidence in the insurer's strong earnings and global expansion efforts. MetLife surpassed quarterly EPS expectations and saw significant revenue growth, driven by its diversified business model across the U.S., Asia, Latin America, and EMEA. This analyst optimism, combined with the company's solid financial performance and strategic asset management, suggests potential upside for investors seeking reliable dividends and growth.

Apple TV is expanding its reach by becoming available as an add-on subscription through Amazon Prime Video in the U.S. This partnership will allow Prime members to access Apple's original content, live sports, and shows directly within the Prime Video ecosystem for $9.99 per month, eliminating the need for separate apps. Both companies are prominent in the streaming and tech industries, with this move aiming to enhance content accessibility for consumers and further establish Prime Video as a comprehensive entertainment hub.

Textron Aviation has announced significant upgrades for its Cessna piston aircraft models, including the integration of Garmin G1000 NXi System Release 7 avionics and a Lycoming dual electronic ignition system, expected to be operational by late 2026 to early 2027. Despite a strong GF Score™ of 90, indicating high profitability and financial strength, the company has seen $30 million in insider sales over the past three months with no purchases, which could be a concern for investors. Textron's P/E ratio of 17.86x is also near its 1-year high, suggesting a potentially high valuation.

Amgen's bispecific T-cell engager tarlatamab has received regulatory approval in China for adult patients with extensive-stage small cell lung cancer whose disease progressed after chemotherapy. Marketed as Imdelltra in the US, the drug demonstrated significant clinical benefits in the Phase II DeLLphi-301 study, including a 46.3% objective response rate and a median overall survival of 19.0 months, with a manageable safety profile. The approval expands Amgen's oncology presence in a major cancer market, with analysts projecting potential annual global sales exceeding $2 billion.

Raymond James Financial has initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with an "Outperform" rating and a $108 price target, indicating a potential 52% upside. This follows a significant quarterly earnings miss for PTC Therapeutics, with reported EPS of -$1.67 against an expected -$0.21, and revenue of $164.7M versus $281.5M anticipated. Despite insider stock sales totaling approximately $8.5 million in the past 90 days, the company holds a "Moderate Buy" consensus rating from analysts with an average target price of $84.40.

BNP Paribas Exane has lowered its price target for Fidelity National Information Services (NYSE:FIS) to $40.00 from $47.00, maintaining an "underperform" rating, which suggests a potential 10.69% downside. This contrasts with the broader analyst consensus of a "Moderate Buy" with an average price target of $68.95. The report also highlights that FIS slightly missed Q4 EPS expectations but beat on revenue, and its CEO recently purchased a significant amount of company stock.

JPMorgan Chase & Co. has lowered its price target for Illinois Tool Works (NYSE:ITW) to $303.00 from $327.00, while maintaining an "overweight" rating. This new target implies a potential upside of approximately 10.7% from the stock's current price. Analyst sentiment for ITW is mixed-to-negative, with a consensus rating of "Reduce" and an average target price of $270.00, despite the company recently beating earnings estimates and providing solid FY2026 guidance.

Wells Fargo & Company has lowered its price target for PPG Industries (NYSE:PPG) from $135 to $130, while maintaining an "overweight" rating, suggesting a 17.39% upside. This adjustment follows PPG missing expected quarterly EPS ($1.51 vs. $1.57) despite a 5% year-over-year revenue increase and setting its FY2026 EPS guidance between $7.70 and $8.10. The consensus analyst rating for PPG remains a "Hold" with an average price target of $120.14.

Phillips 66's Iron Mesa plant in the Permian Basin is advancing to its next construction phase with strong safety performance, having logged over 77,000 safe work hours. This project is crucial for processing growing natural gas production in the Permian, converting raw gas into usable products like pipeline-quality gas and natural gas liquids. Iron Mesa, with its 300 MMscfd capacity, will enhance Phillips 66's Midstream network and complement existing infrastructure to efficiently deliver energy to markets.

The Village at Shirlington's ongoing renovations will introduce two new pet relief areas, located outside Dogma Bakery and Shirlington Animal Hospital. These areas will replace an existing large planter and feature crushed stone and boulders with hose bibbs for regular washing. The broader renovation project focuses on pedestrian-oriented upgrades, including expanded sidewalks, new signage, improved lighting, and public art installations, with the final phase of construction expected to conclude in November.